BAX vs. PODD, TFX, GMED, RMD, DXCM, BDX, SWAV, SOLV, WST, and PEN
Should you be buying Baxter International stock or one of its competitors? The main competitors of Baxter International include Insulet (PODD), Teleflex (TFX), Globus Medical (GMED), ResMed (RMD), DexCom (DXCM), Becton, Dickinson and Company (BDX), Shockwave Medical (SWAV), Solventum (SOLV), West Pharmaceutical Services (WST), and Penumbra (PEN). These companies are all part of the "surgical & medical instruments" industry.
Baxter International (NYSE:BAX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.
Baxter International has higher revenue and earnings than Insulet. Baxter International is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.
Baxter International has a net margin of 17.79% compared to Insulet's net margin of 13.14%. Insulet's return on equity of 34.06% beat Baxter International's return on equity.
Baxter International received 16 more outperform votes than Insulet when rated by MarketBeat users. Likewise, 66.18% of users gave Baxter International an outperform vote while only 66.05% of users gave Insulet an outperform vote.
90.2% of Baxter International shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 0.5% of Insulet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Baxter International had 11 more articles in the media than Insulet. MarketBeat recorded 20 mentions for Baxter International and 9 mentions for Insulet. Insulet's average media sentiment score of 1.28 beat Baxter International's score of 0.31 indicating that Insulet is being referred to more favorably in the news media.
Baxter International presently has a consensus target price of $45.18, suggesting a potential upside of 33.04%. Insulet has a consensus target price of $239.44, suggesting a potential upside of 33.70%. Given Insulet's stronger consensus rating and higher probable upside, analysts plainly believe Insulet is more favorable than Baxter International.
Baxter International has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.
Summary
Insulet beats Baxter International on 10 of the 18 factors compared between the two stocks.
Get Baxter International News Delivered to You Automatically
Sign up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baxter International Competitors List
Related Companies and Tools
